Literature DB >> 1586145

Motor nerve biopsy in severe Guillain-Barré syndrome.

S M Hall1, R A Hughes, P F Atkinson, I McColl, A Gale.   

Abstract

We undertook a biopsy of a terminal branch of the musculocutaneous nerve in a man with severe Guillain-Barré syndrome and very small distally evoked action potentials. The biopsy showed pronounced subperineurial edema, macrophage infiltration, and many axons that had been completely demyelinated, some associated with intratubal macrophages. The biopsy unequivocally identified the pathological process as primary demyelination, not axonal degeneration, and was more informative than previous reports of sural nerve biopsies in patients with Guillain-Barré syndrome.

Entities:  

Mesh:

Year:  1992        PMID: 1586145     DOI: 10.1002/ana.410310416

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

Review 1.  Acute neuromuscular respiratory paralysis.

Authors:  R A Hughes; D Bihari
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

Review 2.  Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.

Authors:  Eroboghene E Ubogu
Journal:  Acta Neuropathol       Date:  2015-08-12       Impact factor: 17.088

Review 3.  Biology of the human blood-nerve barrier in health and disease.

Authors:  Eroboghene E Ubogu
Journal:  Exp Neurol       Date:  2020-03-03       Impact factor: 5.330

4.  Guillain-Barré syndrome as an extraintestinal manifestation of Crohn's disease.

Authors:  R de la Fuente-Fernández; E Rubio-Nazabal; F de la Iglesia-Martínez
Journal:  Postgrad Med J       Date:  1995-07       Impact factor: 2.401

5.  Re-evaluating the accuracy of optimized electrodiagnostic criteria in very early Guillain-Barré syndrome: a sequential study.

Authors:  Velina Nedkova; Gerardo Gutiérrez-Gutiérrez; Francisco J Navacerrada-Barrero; José Berciano; Carlos Casasnovas
Journal:  Acta Neurol Belg       Date:  2021-02-18       Impact factor: 2.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.